Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.
Transduction with chimeric T-cell receptor genes can be used to redirect primary T lymphocytes to recognize specific antigens (Ags), including ovarian and breast cancer Ags. To extend this approach to colon cancer we report here redirection of T cells using a chimeric receptor recognizing the colon cancer-associated Ag EGP40. Chimeric T cell receptors were constructed by ligating single-chain genes of either of two EGP40-specific monoclonal antibodies (CO17.1 A, GA733) to the Fc receptor gamma-signaling chain. Retroviral vectors incorporating these constructs were used to transduce a murine T-cell line and human peripheral blood lymphocytes. These modified T cells were analyzed for specific recognition of colon cancer lines by measuring cytokine release and lytic activity against tumor targets. Murine lymphocytes transduced with the chimeric receptor based on GA733, but not CO17.1A, released cytokine specifically in response to EGP40-expressing colon cancer cell lines. Recognition of colon cancer targets by murine lymphocytes was blocked by the addition of GA733 antibody or soluble EGP40 Ag, confirming that colon cancer recognition is based on specific chimeric receptor-Ag interaction. Human lymphocytes transduced with chimeric GA733 specifically recognized colon carcinoma cells in cytokine release assays and lysed EGP40-expressing tumor cells. Genetic modification of T cells can be used to redirect T cells against EGP40-expressing tumor cells. The expression of chimeric GA733 in the autologous lymphocytes of patients may provide a source of tumor-reactive cells with therapeutic application against colon cancer.
Daly
T
T
Tumor Immunology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Royal
R E
RE
Kershaw
M H
MH
Treisman
J
J
Wang
G
G
Li
W
W
Herlyn
D
D
Eshhar
Z
Z
Hwu
P
P
D016475:3T3 Cells; D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000096:biosynthesis / Q000378:metabolism; D002460:Cell Line; D003110:Colonic Neoplasms / Q000235:genetics / Q000276:immunology* / Q000378:metabolism* / Q000628:therapy; D000071858:Epithelial Cell Adhesion Molecule; D006801:Humans; D020014:K562 Cells; D051379:Mice; D011948:Receptors, Antigen, T-Cell / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D017452:Receptors, IgG / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism* / Q000821:virology; D014162:Transfection / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D000071858:Epithelial Cell Adhesion Molecule; D011948:Receptors, Antigen, T-Cell; D017452:Receptors, IgG; D011993:Recombinant Fusion Proteins